Researchers at Northwestern Medicine have identified immune system markers that may help predict which patients respond to BCG bladder cancer therapy and which do not, according to findings published in the Journal of Clinical Investigation. The discovery could lead to more personalized treatment approaches for bladder cancer, a disease that affects thousands of patients annually.
BCG (bacillus Calmette-Guérin) therapy is a standard immunotherapy for high-risk non-muscle invasive bladder cancer. However, up to 40% of patients do not respond to the treatment, often leading to disease progression. Until now, there has been no reliable way to predict which patients will benefit. The Northwestern team analyzed tumor samples and identified specific biomarkers that indicate a patient's immune system is primed to respond to BCG. These biomarkers include expression patterns of certain genes and proteins involved in immune activation.
The study's lead author, Dr. Joshua Meeks, emphasized the importance of these findings. "We've been treating bladder cancer patients with BCG for decades without knowing why some respond and others don't. These biomarkers give us a window into the immune microenvironment and could help us identify those most likely to benefit," Meeks said. The findings were published in the Journal of Clinical Investigation.
The discovery comes as companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) continue to refine immunotherapy approaches for cancer. While Calidi focuses on novel stem cell-based platforms, the Northwestern research underscores the broader potential of immune biomarkers in guiding treatment decisions.
The implications of this research are significant. Bladder cancer is the sixth most common cancer in the United States, with an estimated 82,000 new cases each year. BCG therapy is the gold standard for high-risk disease, but its failure in many patients leads to cystectomy (bladder removal) and reduced quality of life. If validated, these biomarkers could allow clinicians to identify non-responders early and offer alternative treatments, such as checkpoint inhibitors or clinical trials.
"This is a step toward precision medicine in bladder cancer," Meeks added. "Our goal is to spare patients from ineffective treatments and their side effects." The researchers plan to validate the biomarkers in larger clinical trials and are exploring collaborations to develop a clinical test. The findings also highlight the importance of immune profiling in cancer care, moving beyond one-size-fits-all approaches.
